Abstracts tagged "Cytokines and vasculitis"

Abstract Number: 1766 • 2019 ACR/ARP Annual Meeting
GM-CSF Is a Pro-Inflammatory Cytokine in Experimental Vasculitis of Medium and Large Arteries
Ryu Watanabe ¹, Hui Zhang ², Toshihisa Maeda ³, Mitsuhiro Akiyama ², Rohan Gandhi ⁴, John Paolini ⁵, Gerald Berry ¹ and Cornelia Weyand², ¹Stanford University, Stanford, ²Stanford University, Stanford, CA, ³Matsubara Mayflower Hospital, Kobe, Japan, ⁴Kiniska Pharmaceuticals, San Diego, ⁵Kiniska Pharmaceuticals, Lexington, MA
Background/Purpose: Giant Cell Arteritis (GCA) is a granulomatous vasculitis with tissue tropism for medium and large arteries. Macrophages are a key cellular component of the…
Abstract Number: 874 • 2016 ACR/ARHP Annual Meeting
Expression and Function of IL-12/23 Related Cytokine Subunits (p35, p40 and p19) in Giant-Cell Arteritis Lesions. Potential Role of p40 in Promoting Th1 -Mediated Pathways
Georgina Espígol-Frigolé¹, Ester Planas-Rigol¹, Ester Lozano², Marc Corbera-Bellalta², Nekane Terrades-Garcia², Sergio Prieto-González¹, Ana García-Martínez³, Jose Hernández-Rodríguez² and Maria C. Cid⁴, ¹Department of Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ²Vasculitis Research Unit. Department of Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ³Emergeny Department, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ⁴Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain
Background/Purpose: GCA has been considered a Th1-mediated disease. In recent years it has become apparent that Th17-mediated mechanisms may also play a role in GCA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].